FIELD: pharmaceuticals.
SUBSTANCE: invention relates to a compound of formula (I), where the values of R1, R2, R3, R5, R6, X, Y, Z1-Z4, m, n are defined in the formula of the invention, its stereoisomer or pharmaceutically acceptable salt, which has high activity against mutant forms of FGFR. The following is also proposed: a method of producing a compound containing a pharmaceutical composition thereof, its use for the production of a medicinal product intended for the treatment and/or prevention of tumors or malignancies mediated by FGFR kinase, as well as for the treatment of a patient with a tumor resistant to an FGFR inhibitor, in particular its use for obtaining a medicinal product intended for the treatment and/or prevention of a patient with a tumor carrying mutations V561, V565, N550, N540, V555, E566, K660 and/or V550 in the FGFR-dependent signaling pathway.
EFFECT: obtaining of FGFR and its mutation inhibitor and a method of its preparation and use.
23 cl, 2 tbl, 78 ex
| Title | Year | Author | Number |
|---|---|---|---|
| AZAINDOL DERIVATIVES AS FACTOR Xa INHIBITORS | 2004 |
|
RU2330853C2 |
| CD73 INHIBITOR, ITS PRODUCTION METHOD AND ITS USE | 2020 |
|
RU2787428C1 |
| N-(AZAARYL)CYCLOLACTAM-1-CARBOXAMIDE DERIVATIVE, ITS PREPARATION METHOD AND ITS APPLICATION | 2018 |
|
RU2765785C2 |
| INHIBITOR OF EGFR AND PRODUCTION AND USE THEREOF | 2015 |
|
RU2702631C2 |
| PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | 2014 |
|
RU2677653C2 |
| TYPE 1 DIACYLGLYCEROL-O-ACYLTRANSFERASE ENZYME INHIBITORS | 2008 |
|
RU2486186C2 |
| FGFR INHIBITOR, METHOD FOR PRODUCTION AND APPLICATION THEREOF | 2019 |
|
RU2771526C1 |
| NEW DIAMIDES PYRIMIDIN-4,6 OF DICARBOXYLIC ACID FOR SELECTIVE INHIBITION OF COLLAGENASES | 2003 |
|
RU2344129C2 |
| BICYCLIC HETEROCYCLIC COMPOUNDS AND THEIR APPLICATIONS | 2020 |
|
RU2811612C2 |
| ANTIVIRAL COMPOUNDS | 2009 |
|
RU2505539C2 |
